Literature DB >> 29949738

Current Readings: Single vs Bilateral Internal Mammary Artery in Coronary Artery Bypass Grafting.

Julius I Ejiofor1, Tsuyoshi Kaneko1, Sary F Aranki2.   

Abstract

There is strong retrospective data demonstrating that bilateral internal mammary artery (BIMA) grafting leads to better long-term survival as compared to left internal mammary artery grafting. However, this survival advantage was not corroborated by the interim results of the Arterial Revascularization Trial. Today, there are barriers to widespread adoption of BIMA grafting. One of the main disadvantages of the use of BIMA grafts is the higher risk of deep sternal wound infection. Deep sternal wound infections can be minimized by skeletonized harvesting of the internal mammary artery grafts, which preserve blood flow to the sternum. Also, utilizing the BIMA graft as a "Y" graft may lead to more complete revascularization compared to its in situ use. BIMA grafting on average takes 25 minutes longer operating time with a higher in-hospital costs. We eagerly await the 10-year results of the Arterial Revascularization Trial to determine the truly unbiased randomized long-term effectiveness of BIMA grafting.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  BIMA; CABG; LIMA

Mesh:

Year:  2018        PMID: 29949738     DOI: 10.1053/j.semtcvs.2018.05.004

Source DB:  PubMed          Journal:  Semin Thorac Cardiovasc Surg        ISSN: 1043-0679


  2 in total

1.  Quality of life in patients after coronary artery bypass grafting with bilateral internal thoracic artery versus single internal thoracic artery.

Authors:  Marcin Zębalski; Jarosław Bis; Michał Krejca; Marek A Deja
Journal:  Kardiochir Torakochirurgia Pol       Date:  2020-04-07

Review 2.  Impact of Bilateral versus Single Internal Thoracic Artery Grafting on the Long-Term Survival in Adults: A Systematic Review.

Authors:  Montaser Nabeeh Al Smady; Mohammed Nagdi Zaki; Eman Alataywi; Olivier Jegaden
Journal:  Vasc Health Risk Manag       Date:  2021-08-25
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.